TABLE 3.
Anti-proliferative activity of compounds 1–13 and 15–26 against HepG2 cells.
Compound | IC50 (μM) | Compound | IC50 (μM) |
---|---|---|---|
1 | >50 | 15 | >50 |
2 | >50 | 16 | >50 |
3 | >50 | 17 | 25.59 ± 0.41 |
4 | >50 | 18 | >50 |
5 | >50 | 19 | 2.30 ± 0.30 |
6 | >50 | 20 | >50 |
7 | >50 | 21 | >50 |
8 | >50 | 22 | >50 |
9 | >50 | 23 | >50 |
10 | >50 | 24 | >50 |
11 | >50 | 25 | >50 |
12 | >50 | 26 | >50 |
13 | >50 | — | — |
Gemcitabine (GEM) was used as a positive control with an IC50 value of 2.32 ± 0.99 μM.